Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | ALDH2 | P05091 | 7/20 | 1.00 |
| ▸ | ALDH3A1 | P30838 | 7/20 | 1.00 |
| ▸ | PARK7 | Q99497 | 6/20 | 0.71 |
| ▸ | CA12 | O43570 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16798714 | 0.87 | ALDH3A1 (1.00) | ALDH1A1ALDH2ALDH3A1CA12CA1 | |
| SCHEMBL16799029 | 0.83 | ALDH1A1 (1.00) | ALDH1A1ALDH2ALDH3A1PARK7CA12 | |
| SCHEMBL16048068 | 0.83 | ALDH1A1 (0.71) | ALDH1A1ALDH2ALDH3A1PARK7CA12 | |
| SCHEMBL4597126 | 0.82 | ALDH1A1 (0.77) | ALDH1A1ALDH2ALDH3A1PARK7CASP3 | |
| SCHEMBL9384529 | 0.82 | DRD2 (0.74) | ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL16112176 | 0.82 | ALDH3A1 (0.71) | ALDH1A1ALDH2ALDH3A1PARK7CASP3 | |
| SCHEMBL16799085 | 0.82 | ALDH1A1 (1.00) | ALDH1A1ALDH2ALDH3A1PARK7CA12 | |
| Hydrochloric Acid SCHEMBL9096836 | 0.81 | DRD2 (0.72) | ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL28533366 | 0.80 | ALDH3A1 (0.67) | ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL16048101 | 0.79 | ALDH3A1 (0.65) | ALDH1A1ALDH2ALDH3A1PARK7CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920029-B2 | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920029-B2 | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2018-03-20 | — | — | US | disclosed |
| US-9920029-B2 | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2018-03-20 | — | — | US | disclosed |
| EP-2970183-A2 | ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | Musc Foundation for Research Development (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150218128-A1 | Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders | MUSC Foundation for Research Development (10 pp.) | 2015-08-06 | — | — | US | disclosed |
| US-20150218128-A1 | Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders | MUSC Foundation for Research Development (10 pp.) | 2015-08-06 | — | — | US | disclosed |
| US-20150218128-A1 | Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders | MUSC Foundation for Research Development (10 pp.) | 2015-08-06 | — | — | US | disclosed |
| US-9079853-B2 | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079853-B2 | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079853-B2 | Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2015-07-14 | — | — | US | disclosed |
| WO-2015084731-A1 | ALDEHYDE DEHYDROGENASE INHIBITORS AND METHODS OF USE THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2014160143-A2 | ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20140275075-A1 | ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275075-A1 | ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275075-A1 | ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218128-A1 | Isatin Compounds, Compositions And Methods For Treatment Of Degenerative Diseases And Disorders | CLN6, AREG, HASPIN | ALDH1A1 751/4885ALDH2 522/4885ALDH3A1 1316/4885 |
| US-20140275075-A1 | ISATIN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DEGENERATIVE DISEASES AND DISORDERS | CLN6, AREG, HASPIN | ALDH1A1 751/4885ALDH2 522/4885ALDH3A1 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.